arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Upstream Bio, Inc.

UPB
$7.23 ▲ +0.36 (+5.16%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
14 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

Upstream Bio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $392.8M
Dividend Yield
Revenue Growth 82.7%
Op. Margin
ROIC -11.3%
FCF / Share $-0.88
Trailing P/E
Price / Book 1.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.03M
↑ +82.7%
Net Income Profit after all expenses
$-40.59M
↓ -48.8%
FCF / Share Free cash flow per share
$-0.88
↓ -14.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
19
Cash Quality
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 14 quarters